Postgraduate research opportunities Development of novel Inhibitors of CXCL12 production as new medicines for cancer and inflammation


Key facts

  • Opens: Monday 16 November 2020
  • Number of places: 1
  • Duration: 36 Months


CLXL12, cancer, Nuclear factor kappa B, signalling, molecular. Cellular Basis of disease/Drug discovery
Back to opportunity


Background in Biology, Biochemistry or Pharmacology

THE Awards 2019: UK University of the Year Winner
Back to opportunity

Project Details

CXCL12 is a chemokine known to affect a number of important cellular events.  Recent studies have implicated it in a number of disease such as cancer, arthritis and atherosclerosis.  Inhibitors of the receptor for CXCL12, CXCR4, have been developed but have been found to have limited clinical success. An alternative strategy is to prevent the expression of CXCL12 as a means to inhibit its function.  Using an initial CXCL12 assay screen we have uncovered a number of potential novel inhibitors.  The project will assess the site and mechanism of action of these inhibitors and assess their potential as novel drugs for treatment of disease.  At the same time molecular approach will allow understanding of signalling events linked to CXCL12 to be explored.


Techniques used:

Cell culture, western blotting, imaging, gene array, FACS analysis, siRNA.

Further information

Project is suitable to be undertaken as PhD Plus 

Back to opportunity

Funding details

Applicants must be able to fund tuition and bench fees throughtout studies

Back to opportunity


Professor Robin Plevin

Strathclyde Institute of Pharmacy and Biomedical Sciences

View profile
Dr Kathryn McIntosh

Research Fellow
Strathclyde Institute of Pharmacy and Biomedical Sciences

View profile
Back to course

Contact us

Primary Supervisor: Professor Robin Plevin